Table 3. CI values for the investigated combinations in PANC-1 cells.
Compound combination | Combination ratio | CI valuesa at effect level of | CIwt valuesb | Assigned symbolc | |
---|---|---|---|---|---|
75% | 90% | ||||
cisplatin + beta-escin | 1 : 1.247 | 1.007 (1.015 +/- 0.239) |
0.826 (0.845 +/- 0.320) |
0.868 | + |
cisplatin + camptothecine | 1 : 0.083 | 0.345 (0.341 +/- 0.069) |
0.245 (0.242 +/- 0.071) |
0.376 | +++ |
cisplatin + daunorubicin | 1 : 0.022 | 0.680 (0.670 +/- 0.147) |
0.449 (0.453 +/- 0.149) |
0.552 | +++ |
cisplatin + hycanthone | 1 : 0.250 | 0.837 (0.836 +/- 0.139) |
0.614 (0.616 +/- 0.150) |
0.665 | +++ |
cisplatin + topotecan | 1 : 0.250 | 0.395 (0.392 +/- 0.070) |
0.277 (0.275 +/- 0.075) |
0.340 | +++ |
cisplatin + vorinostat | 1 : 0.749 | 0.495 (0.492 +/- 0.074) |
0.305 (0.303 +/- 0.068) |
0.361 | +++ |
carboplatin + aminacrine | 1 : 0.034 | 0.380 (0.389 +/- 0.097) |
0.265 (0.276 +/- 0.109) |
0.302 | +++ |
carboplatin + daunorubicin | 1 : 0.010 | 0.974 (0.976 +/- 0.182) |
0.630 (0.638 +/- 0.220) |
0.727 | ++ |
carboplatin + hycanthone | 1 : 0.101 | 0.524 (0.528 +/- 0.054) |
0.408 (0.414 +/- 0.068) |
0.351 | +++ |
carboplatin + topotecan | 1 : 0.084 | 0.095 (0.097 +/- 0.023) |
0.018 (0.019 +/- 0.008) |
0.077 | +++++ |
oxaliplatin + topotecan | 1 : 1.265 | 0.819 (0.836 +/- 0.241) |
0.824 (0.899 +/- 0.769) |
0.827 | ++ |
a CI values were calculated using CompuSyn [62]; the values in brackets represent the means ± 95% confidence intervals, as determined from the sequential deletion analysis (S.D.A.) as a measure of the CI variability at the presented effect levels (i.e., at IC75 and IC90).
b Weighted average CI values, calculated as follow: CIwt = (CI50 + 2CI75 + 3CI90 + 4CI95)/10.
c Degrees of synergism (+ signs) or antagonism (- signs) are based on the ranges of CIwt values as described in ref. [31]; (±) near additive effect, (+) slight synergism, (++) moderate synergism, (+++) synergism, (++++) strong synergism and (+++++) very strong synergism; antagonism is divided in the same way, except using “-”signs.